Aging
Navigate
Submit an Article
Research Paper|Volume 12, Issue 22|pp 22527—22537

Cationic solid lipid nanoparticles loaded by integrin β1 plasmid DNA attenuates IL-1β-induced apoptosis of chondrocyte

Yuejiang Zhao1, Hanwen Chen1, Lu Wang1, Zhiyuan Guo1, Shijie Liu2, Simin Luo3
  • 1The First Department of Orthopedics, Cangzhou Central Hospital, Cangzhou, Hebei Province, China
  • 2Department of Joint Surgery, Xingtan Hospital Affiliated to Shunde Hospital of Southern Medical University, Foshan, Guangdong Province, China
  • 3Department of Bone and Joint Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China
Received: April 10, 2020Accepted: June 20, 2020Published: November 27, 2020
https://doi.org/10.18632/aging.103656

Copyright: © 2020 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Aging-related inflammation is tightly linked with the development of osteoarthritis (OA). As the pro-inflammatory cytokine, IL-1β has been associated with physical dysfunction and frailty. It is still elusive whether and how IL-1β blockade improves the outcome of OA. Here we develop a cationic solid lipid nanoparticles (SLNs) system that effectively mediate non-viral delivery of plasmid DNA (pDNA) into cells. Compared with other DNA transfer technologies including lipofetamin 2000, SLNs-pDNA system is less toxic and exerts identical effectiveness on DNA transfer. Loaded with integrin β1 overexpression pDNA, the SLNs-pDNA mainly localized in cytoplasm and enforced expression of integrin β1 in rat chondrocytes. Moreover, upon exposure to IL-1β stimulation, SLNs-pDNA treatment attenuates the apoptosis rat chondrocytes and augments tissue repair. Our data thus demonstrate that SLNs-pDNA functions as a potential therapeutic nanomedicine in the treatment of osteoarthritis.